Objective: While the survival of extremely premature infants has improved over the past decades, the rate of complications -especially for bronchopulmonary dysplasia (BPD) -remains unacceptably high. Over the past 50 years, no safe therapy has had a substantial impact on the incidence and severity of BPD.
INTRODUCTION

Bronchopulmonary Dysplasia: Recognizing the Complexity and Challenge to Treat
Great advances in perinatal medicine have improved the survival of extreme low birth weight infants but this success has been tempered by the fact that these infants have an unacceptably high risk for developing complications such as Bronchopulmonary Dysplasia (BPD). Recent cohort studies report that the incidence of BPD in extremely low birth weight infants ranging between 30 to 70% [1] [2] [3] [4] [5] . It has been almost half a century since BPD was first described by Northway and colleagues in 1967 [6] but a cure for BPD still remains unavailable. The complexity of this debilitating chronic lung disease has hampered the discovery of efficient therapies. BPD remains the most common cause of morbidity and mortality in this group of infants [7] [8] [9] .
Over the past five decades, as a result of the increasing survival of more premature infants, the disease pathogenesis has changed: Compared to the lung histology observed in premature infants before the surfactant era, the "new" BPD is characterized by a significant reduction in alveolarisation *Address correspondence to this author at the Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute (OHRI), 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada; E-mail: bthebaud@ohri.ca and vascularization. BPD now represents a combination of interruption of normal developmental signaling during early stages of lung development and a dysregulated repair process in response to perinatal insults (including inflammation, oxidative stress, and others) [10] [11] [12] .
Postnatal corticosteroids, vitamin A, caffeine, lungprotective ventilation strategies, have been explored in large clinical trials but proven to be of limited success or unsafe in preventing BPD. Follow-up studies raised concerns about certain therapies such as dexamethasone due to its side effects especially on the premature brain [13] [14] [15] . Recent insights into stem cell biology have highlighted the potential use of these cells in regenerative medicine. Indeed, cell based-therapies have now advanced to be one of the most promising avenues for tissue repair including the preterm lung. More recent evidence suggesting dysfunction of resident lung stem cells in human lung diseases and animal models of BPD [16] provide further rationale for exogenous cell-based therapies to supplement the impaired endogenous repair mechanisms. both self-renewal and multilineage differentiation (potency). Totipotent stem cells are the earliest cells in the ontogeny and extend from the zygote to the inner cell mass of the blastocyst. They are capable of differentiating into all adult, embryonic and extraembryonic tissues. Embryonic Stem Cells (ESC) are pluripotent stem cells capable of differentiating into derivatives of all three germ cell layers (ectoderm, mesoderm and endoderm). Multipotent stem cells are more restricted and give rise to multiple cell types of one lineage, such as Hematopoietic Stem Cells (HSCs). Residual pools of multipotent or unipotent stem cells are hypothesized to reside in almost all adult organs, contributing to their ability to repair and regenerate after injury [12, [17] [18] [19] [20] .
Their ability to self-renew and regenerate after damage maybe limited naturally due to advancing age and extent of the disease [21] . This can occur secondary to depletion of the residual stem cell pools or as a consequence of genetic or microenvironmental changes that prevent proper stem cell renewal and function. These changes can potentially be reversed via stimulation of the endogenous stem cell pools or the replacement/supplementation of exogenous stem cells. Such exogenous stem cell replacement therapies have been used for decades for hematological disorders using Bone Marrow (BM) derived HSCs and increasingly for treating debilitating metabolic disorders [22] [23] [24] [25] [26] [27] .
HSCs are dependent on the proper function of their niche cells: mesenchymal stromal cells (MSCs). Over the past two decades, the recognition of the repair capabilities of these cells, has advanced MSCs as the most promising cell therapy for organ regeneration. This is in part due to their pleiotropic effects, including immune modulation [28, 29] , angiogenesis [30, 31] , and anti-oxidant activity [32, 33] , appealing properties for the treatment of a multifactorial disease, such as BPD.
MSCs: FROM NICHE CELLS TO POTENT REPAIR CELLS
MSCs were first described by Friedenstein and coworkers as adherent, fibroblast-like cells isolated from BM, stroma of the spleen and thymus [34, 35] . MSCs can differentiate into mesodermal lineage cells including osteoblasts, adipocytes, and chondrocytes in vitro and have the capability to self-renew. Since, MSCs have been isolated from almost every tissue, including adipose tissue [36] , skeletal muscles [37] , synovium [38] , circulatory system [39] , dental pulp [40] , spleen, liver, kidney [41] , umbilical cord [42] , amniotic fluid [43] , fetal blood, lung, liver and BM [44, 45] .
Since its discovery in 1970s, MSCs have generated increasing interest but reported studies used different methods of isolation and expansion and different approaches to characterize the cells. In 2006, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) proposed minimal criteria to define human MSCs [46] : 1. MSC must be plastic adherent when maintained in standard culture conditions using tissue culture flasks.
Phenotype:
• 95% of the MSC population must express CD105, CD73, and CD90, as measured by flow cytometry.
• Must lack expression ( 2% positive) of CD45, CD34, CD14, or CD11b, CD79 or CD19 and HLA class II. A milestone indicating the potential of MSC replacement in organ repair occurred in 1999 when Makino S. and colleagues isolated a Cardiomyogenic Cell Line (CMG) from murine BM stromal cells. After treatment with 5-azacytidine, these cells changed morphology and acquired cardiomyocyte-like ultrastructure, including synchronous beating rhythm and expression of atrial natriuretic peptide and brain natriuretic peptide [47] . Shake J. G. and colleagues showed that MSCs engrafted in host myocardium, expressed muscle specific proteins and improved contractile dysfunction in the swine model of left ventricular wall infarction [48] . Although it was subsequently recognized that tissue engraftment is not the main mechanism of action of MSCs, their therapeutic benefit has been demonstrated extensively in acute lung injury [49, 50] , acute and chronic kidney injuries [51] [52] [53] , acute pancreatitis [54] , liver fibrosis [55] and autoimmune encephalitis [56, 57] .
Currently, there are more than six hundred clinical trials utilizing MSCs being conducted for adult diseases, such as in heart failure, inflammatory bowel disease, asthma, acute respiratory distress syndrome, cystic fibrosis, idiopathic lung fibrosis, osteoarthritis, diabetes mellitus, and various neurological diseases.
MSCs AND PRECLINICAL STUDIES IN BPD
Animal Models
In order to determine the beneficial effect of MSCs in human premature lung, various animal models have been explored to mimic the pathological features of BPD [58] . Rodents (rat and mice) exposed to hyperoxia have been widely used. While these rodents are not delivered preterm and are otherwise healthy, the advantages of this model include birth at the saccular stage (equivalent to 26-28weeks of human gestation) of human lung development. [59, 60] , low cost, fast turnaround, low maintenance, making this model ideal for rapid proof of concept experiments. Premature rabbits, lambs and piglets have also been employed to mimic BPD. The need for preterm delivery requires the need for mechanical ventilation and other life-sustaining interventions, making these models more clinically relevant, but labor intense and expensive [61] [62] [63] [64] . The other interesting model using prematurely delivered baboon at 125 days (equivalent to 27 weeks of human gestation) and mechanically ventilated for 2 weeks offers great opportunity to test the effect of MSCs therapy in a model very close to the human setting [65] . These large animal models allow ultimate feasibility, safety and efficacy studies that may be required for regulatory approval of cell products.
Proof of Concept in Rodent Models of BPD for Testing the Therapeutic Benefits of MSCs
In 2007, Tian and colleagues has shown that Intravenous (IV) injection of 5x 10
4 (approximately 5 x 10 6 /kg) BM derived MSCs (BM-MSCs) improves radial alveolar count and reduces inflammatory cytokines [Tumor Necrosis Factor Alpha (TNF ) and Transforming Growth Factor Beta-1 (TGF -1)] in the rat model exposed to 95% O 2 [66] . This finding is supported by Aslam and colleagues in 2009, who showed normalized lung structure with attenuation in vascular remodeling in hyperoxic mice by IV BM-MSC injection [67] . Subsequent studies confirmed the same beneficial effects in the hyperoxic rat model [68] [69] [70] [71] .
Besides the IV route, intratracheal (IT) administration has been investigated by van Haaften and colleagues in 2009. In this prevention study, BM-MSCs improve survival, exercise tolerance and lung structure and reduce vascular changes secondary to pulmonary hypertension [72] . The benefits of this route are further supported by Chang and colleagues in 2011, 2013, Ahn and colleagues in 2015, Sung and colleagues in 2015 and Kim and colleagues in 2016 [73] [74] [75] [76] [77] . Most of these animal studies seem to indicate that early MSC replacement confers better lung protection than late therapy.
The efficacy and safety of Human Umbilical Cord/Cord Blood (HUC/B) derived MSCs in these animal models (xenogeneic therapy) suggest that allogenic transplantation is feasible in the clinical setting. The concept of harvesting HUC/B-MSCs after extreme premature delivery for autologous transplantation later to prevent or rescue BPD is worth considering, without jeopardizing the benefits of delayed cord clamping or umbilical cord milking. Alternatively, a ready to use, off-the-shelf MSC product may be logistically easier. Interestingly, Di Bernado and colleagues found that placenta derived MSCs (PL-MSCs) are as potent as BMMSCs in terms of increasing alveolar surface area, branching morphogenesis and stimulating surfactant production in an in vitro study [78] . In an in vivo study using the combined perinatal inflammation and hyperoxic lung injury rat model, IT PL-MSCs reduces inflammatory cytokines and improves lung structure and vascular density [79] . The beneficial effects of MSCs are not only limited to the lung as IT injection of HUCB-MSCs has been shown to reduce brain inflammation and neuronal apoptosis [77] .
Long Term Effects of MSCs
It is prudent to consider the potential long-term side effects of MSCs replacement therapy in the preclinical setting before pursuing clinical trials. In 2013, Pierro and colleagues have studied the short-and long-term effects of IT injection of both HUCB-MSCs and HUC derived perivascular cells (HUC-PCs, putative precursors of MSCs) as both preventive or rescue therapy in the hyperoxic rat model. Their study shows improved alveolar growth, improved lung compliance and reduced pulmonary hypertension in the short term, with long term preserved exercise tolerance and alveolar structure at 6 months of age. There were no observed side effects including tumor formation at 6 months [80] . The same safety profile is observed in the studies by Sutsko and colleagues at postnatal day 100 and by Ahn and colleagues at postnatal day 70 [81, 82] .
Paracrine Effect of MSCs: Medicinal Signaling Cells [83] with Pleiotropic Effects
Low Cell Engraftment
The initial working hypothesis stipulated that MSCs would replace injured cells by engrafting and differentiation into the target cell type (heart, kidney, lung etc). However, contrary to this cell replacement hypothesis, very few engrafted cells could be found [84] . In the newborn rat BPD model, a low number of MSCs engraft as visualized by deconvolution microscopy and quantified by qRT-PCR, respectively [72, 80] . The observed engraftment of MSCs in the lung ranges from 0 to 20 percent in the majority of studies [52] [53] [54] [55] . There is emerging evidence that most of the beneficial effects of stem cell therapy are due to cell-derived paracrine factors, rather than cell engraftment [85] . Tropea and colleagues in 2012 show that treatment of bronchoalveolar stem cells with MSCs derived conditioned media increases their growth efficiency, which might contribute to lung repair after injury [68] . However it is still unknown whether utilizing conditioned-media replacement alone will be superior to MSCs transplantation.
MSCs as Potent Immune Modulators
MSCs interact with cells of the innate and adaptive immune systems [86] . MSCs suppress inflammation, via their soluble factors, including interleukin(IL)-6, M-CSF, IL-10, TGF and prostaglandin E2 [87] [88] [89] . MSCs upregulate antiinflammatory Th2 cytokines, including IL-3, IL-5, IL-10 and IL-13 and downregulate proinflammatory Th1 cytokines, including IL-1 and , interferon-gamma(IFN ) and TNF [90, 91] , culminating in reduced fibrosis. In the series of in vivo studies by Prockop et al., MSCs secrete TNF stimulating gene/protein (TSG)-6 that reduces the inflammatory response [92] [93] [94] [95] . Furthermore, MSCs display important antiapoptotic properties in vital organ injury [96] . This immune modulation effect has been shown in most of the rodent studies of BPD [66, 67, 69, 71, 73, 76, 77, 79, 85] and is particularly important to attenuate inflammation and cell deaths in BPD and to restore lung and vascular growth.
MSCs are Pro-angiogenic
In addition, prostaglandin E2 enhances the secretion of vascular endothelial growth factor resulting in improved angiogenesis [86] . HUC-MSCs attenuate remodeling after myocardial infarction by pro-angiogenic, anti-apoptotic and endogenous cell-activation mechanisms. All these effects were paracrine mediated [97, 98] . A recent study by Reiter, J. and colleagues showed that this pro-angiogenic effect is enhanced by stromal derived factor-1 that mediates lung regeneration in the rodent model of BPD [99, 100] .
MSCs Enhance Bacterial Clearance
There are also exciting findings regarding the bactericidal properties of MSCs via the secretion of bioactive molecules which are antimicrobial in vitro against Pseudomonas aeruginosa, Staphylococcal aureus and Streptococcal pneumonia [101] . In vivo, BM-MSCs infused into septic mice [102] and HUC-MSC into a neonatal Escherichia Coli sepsis model in rats, improve survival and enhance bacterial clearance in part through the production of the antimicrobial peptide LL-37 [103] .
MSCs Display Anti-oxidant Activity
Anti-oxidant effects have been shown to ameliorate various organ injuries such as connective tissues, intestines and spinal cord [104] [105] [106] . Brief hyperoxic pre-conditioning of BM-MSC increases the production of the anti-oxidant stanniocalcin-1 and enhances lung protection in the rodent model of BPD [107] .
These promising preclinical study results have prompted early phase clinical trials to examine the feasibility and safety of MSC therapy in preterm infants at risk of developing BPD.
CLINICAL TRIALS USING MSC FOR BPD
In 2014, Chang and colleagues conducted the first Phase 1 dose-escalation clinical trial in 9 premature infants (mean gestational age 25weeks, mean birth weight 793g) at high risk of developing moderate to severe BPD (NCT01632475). They administered 1x10 7 or 2x10 7 allogeneic HUCB-MSCs via IT route from postnatal day 7 to 14 and observed no immediate or short-term toxicity or adverse events compared to a historical control group [108] . Study participants were subsequently followed up for two years (NCT02023788) and no adverse effects in respiratory status, growth and neurodevelopment were reported [109] . There are currently 3 Phase I and 1 Phase II trials being conducted to assess the safety and efficacy of HUCB-MSCs in preterm infants.
Even though early phase of clinical trials have begun, it is critical to further our knowledge on MSC biology to better understand their exact mechanisms of action and thus optimize the manufacturing process of MSCs.
REMAINING CHALLENGES FOR THE CLINICAL TRANSLATION
Uniformity and Safety of MSC Products
There is abundant evidence in the animal literature that MSCs are lung protective, and it is timely to perform welldesigned early phase clinical trials to advance our understanding about the safety and therapeutic potential of MSCs in preterm infants. A challenge is the careful characterization of clinical-grade MSCs to be used in these trials, because of the many steps in the manufacturing of a cell product [110, 111] . Causes of variations-impacting efficacy and safetyare plentiful and include amongst others: cell source, isolation process, number of passages/doubling times, freezing method, storage, thawing and administration procedure. For example, cryopreservation and thawing can impede MSC function [112] and bio-distribution [113] , whereas a 24-hour culture period post-thawing or IF-licensing restores MSC function [114] . These findings highlight just one of the multiple gaps in our understanding of the biology of MSCs and how to harness their healing potential in the clinic. It also emphasizes the importance for the need of reliable potency assays that predict the therapeutic potential of a given cell product before release and infusion into patients. 
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Potency Assays and Therapeutic Efficacy
In order to further characterize clinical grade MSCs, efforts are focused on redefining MSCs products based on their potency in biological assays rather than their phenotypic characteristics and/or composition [115, 116] . So far, these biological assays have failed to link stem/progenitor properties and effector functions of MSCs and are limited to the anti-inflammatory effect of MSCs [117] [118] [119] . Recently, a Clinical Indications Prediction (CLIP) scale has been proposed to predict the therapeutic efficacy of different human MSC isolates for a given disease indication based on TWIST1 expression levels [120] . The CLIP scale overcomes the aforementioned limitations as it predicts differences in growth, survival, stem/progenitor, and effector function of MSCs. The CLIP scale is a promising attempt that can be further expanded to increase its predictability for the therapeutic efficacy of clinical grade MSC lots for different disease indications in the future. Currently the ISCT proposes a "focused analysis of selected MSC markers robustly deployed by in vitro licensing and metricized with a matrix of assays" to assess a MSC product's biological potency [121] . This step is vital to ensure consistent validity of stem cells clinical trials so those results can be interpreted and compared with confidence.
Cell versus Cell-Free Products
Most of the MSCs' therapeutic effects are mediated via a paracrine activity, as the cell-conditioned media exerts similar (and sometimes superior) therapeutic benefit [85] . Increasing evidence suggests that MSCs derived Extra-cellular Vesicles (EVs) are important players in mediating these paracrine effects [122, 123] . MSCs derived EVs have been shown to promote organ regeneration via its anti-apoptotic activities in kidney [124] , liver [125] , heart [126] , suppressing graft-versus-host disease via its immune-suppressive effects [127] , and ameliorating stroke-associated neurological deficits via promoting neurogenesis and angiogenesis [128] . MSCs derived EVs also attenuate pulmonary arterial hypertension in adult mice [129] . Restoration of lung function in the hyperoxia rat BPD model by MSCs derived EVs has also been demonstrated recently [130] . EVs' therapeutic effects are mediated in part via miRNAs [131, 132] . These cell-free therapies may serve as a safer alternative cell-free therapy to ameliorate lung injury and restore lung and vascular growth in BPD. However, similar to the cell products, challenges in standardization of EV isolation, purification, industrial scale-up and good manufacturing practice compliance, will need to be overcome.
CONCLUSION
BPD still remains the most challenging complication of preterm birth even half a century after its first description. The multifactorial pathological process that leads to BPD makes small molecules and biologics difficult to tackle. MSC therapy emerges as a promising therapy as these cells are able to interact with their microenvironment and display pleiotropic effects by dispensing a variety of injury modulating substances to orchestrate the repair process [111, 133] . Promising preclinical data and the overall safety profile of MSCs have led to first clinical trial in preterm infants even so current cell products are still imperfect. Manufacturing of therapeutic MSCs and/or MSC free products will need to be standardized with its biological effects being tested and verified with approved potency assays before being released for clinical use.
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